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Introduction
The  ‘tranquil’  world  of  hypertension  has  been  disturbed  by  the  emergence  of  a  new
interventional  approach  to  hypertension  management,  namely  renal  denervation  (RDN).
Currently,  RDN  is  only  indicated  for  the  treatment  of  resistant  hypertension  (RH),  and
presents  a  unique  opportunity  to  control  blood  pressure  in  highly  selected  patients  who
are  refractory  to  medical  treatment  (rate  of  control  is  40%  based  on  Symplicity-1  trial  data
[1]).  Considering  the  high  prevalence  of  hypertension,  the  potential  indications  for  such
therapy  are  huge,  provided  that  additional  evidence  conﬁrms,  in  the  future,  the  beneﬁts
of  RDN.
Aims of antihypertensive treatment
This  new  technique  is,  however,  a  source  of  concern  for  hypertension  specialists  because
the  studies  performed  (Symplicity  HTN-1  [1]  and  -2  [2])  have  shifted  the  focus  onto  low-
ering  blood  pressure,  while  for  hypertension  specialists,  the  paradigm  of  hypertension
management  relies  much  more  on  preventing  cardiovascular  events  than  on  lowering  blood
pressure  per  se.  This  has  been  extensively  illustrated  in  the  past  few  decades  by  many  large
clinical  trials  and  meta-analyses  showing  that  some  antihypertensive  regimens  may  provide
beneﬁts  beyond  blood  pressure  lowering.  Further,  ofﬁce  blood  pressure  is  now  considered
to  be  a  poor  surrogate  for  cardiovascular  events,  with  a  greater  value  put  on  central  or
ambulatory  blood  pressure.
Abbreviations: RDN, renal denervation; RH, resistant hypertension.
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evels of evidence
t  present,  RDN  is  far  from  having  the  same  level  of  evidence
s  medical  treatment  for  hypertension,  and  we  are  only  at
he  beginning  of  a  story.  This  could,  of  course,  be  a  source
f  misunderstanding  between  hypertension  specialists  and
nterventional  cardiologists  or  radiologists.  Indeed,  ‘inter-
entionalists’  may  consider  that  this  intervention  is  safe,
asy  and  quick  to  perform,  and  that  it  provides  a  very  sub-
tantial  and  sustainable  blood  pressure  lowering  effect  (for
he  moment,  the  effect  of  RDN  seems  to  persist  to  at  least
 years).  In  addition,  it  may  solve  the  problems  of  compli-
nce  and  imperfect  pharmacokinetics,  and  it  may  present
 radical  and  deﬁnitive  solution.  In  this  respect,  hyperten-
ion  specialists  may  be  considered  too  ‘wise’  with  respect  to
he  potential  beneﬁts  of  this  technique.  However,  if  physi-
ians  are  too  keen  to  propose  RDN,  there  is  a  risk  that  it  will
e  used  for  cases  other  than  RH,  e.g.  patient  preference  or
reatment  intolerance,  that  are  not  supported  by  current
vidence.
here do we stand now with RDN?
ost  of  our  current  knowledge  relies  on  about  100  patients
ncluded  in  a  randomized  trial  (Symplicity  HTN-2  trial  [2]).
lthough  pivotal,  this  study  is  of  limited  size  and  has  some
ethodological  concerns.  In  addition,  no  hard  endpoints
ere  considered,  and  having  analysed  only  ofﬁce  blood
ressure  may  have  overstated  the  blood  pressure  beneﬁt
ompared  with  ambulatory  blood  pressure.  An  ongoing  study
SYMPLICITY  HTN-3  Trial  [3])  as  well  as  the  French  ‘STIC’
ay  help  to  clarify  the  real  blood  pressure  beneﬁt  of  the
echnique.  However,  even  if  future  studies  could  improve
ur  conﬁdence  in  the  technique,  no  outcome  study  has  yet
een  launched.
hy should we try other options before
roposing  RDN?
esistant  hypertension  is  associated  with  a  greater  occur-
ence  of  secondary  forms;  it  is  also  frequently  associated
ith  increased  aldosterone  levels  or  volume  excess  that  can
e  managed  efﬁciently  with  appropriate  treatment,  namely
iuretics.  Proposing  RDN  in  these  cases  would  be  pointless.
A  three-drug-class  regimen  is  now  considered  as  the
ornerstone  of  the  treatment  of  severe  hypertension.  It
ncludes  renin  angiotensin  system  blockers,  calcium  chan-
el  blockers  and  thiazide-like  diuretics  [4].  The  absence  of
lood  pressure  control  with  these  three  treatments  deﬁnes
H  if  high  blood  pressure  is  conﬁrmed  by  ambulatory  mea-
urements  in  Europe.  Having  associated  these  treatments
efore  any  other  option  is  mandatory  for  three  main  reasons:
the  pathophysiology  of  hypertension  is  complex,  some
forms  being  mainly  related  to  volume  excess  and  hyper-
aldosteronism  or  renin  angiotensin  system  activation,
others  to  hypersympathetic  tone,  others  to  vascular  alter-
ation;  these  different  forms  will  not  respond  to  treatment
in  the  same  way;
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these  treatments  not  only  improve  blood  pressure  control,
but  also  prevent  cardiovascular  outcomes;
these  treatments  will  likely  be  maintained  and  even  rein-
forced  after  RDN;  they  should  be  fully  tested  before.
Another  treatment,  spironolactone,  plays  a  major  role  in
H,  and  may  help  to  control  hyperaldosteronism,  which  is
requently  associated  with  RH.  A  marked  improvement  in
lood  pressure  control  in  this  population  could  be  obtained
imply  by  applying  this  systematic  approach  of  treatment
ptimization.  Indeed,  a  recent  report  from  France  showed
hat  only  1/4  of  patients  with  uncontrolled  hypertension
eceive  three  drugs,  while  the  majority  receive  one  or  two
rugs  [5].  RDN  should  not  take  us  away  from  this  basic  but
fﬁcient  generalized  drug-treatment  approach.
It  is  tempting  to  offer  patients  RDN  if  they  suffer  side-
ffects  from  antihypertensive  drugs.  However,  one  has  to  be
autious  because,  over  the  long-term,  slight  ankle  oedema
r  increased  diuresis  may  be  relatively  meaningless  if  some
armful  effect  of  RDN  starts  to  be  observed  at  an  unexpect-
dly  high  frequency  in  the  future  (e.g.  renal  stenosis  or  other
amage  related  to  renal  autoregulation  loss).  This  has  to
e  fairly  considered  before  proposing  this  technique  to  our
atients.
hy should we remain cautious towards
DN?
ssentially,  we  must  be  cautious  because  we  do  not  know
he  real  long-term  consequences  of  this  procedure  on  renal
unction.  Nothing  is  known  about  the  long-term  effects  of
he  kidney  artery  injury  induced  by  RDN.  It  is  conceivable
hat  we  will  observe  ﬁbrotic  stenosis  [6],  and  maybe  some
isturbance  of  kidney  function,  particularly  when  autoregu-
ation  is  needed.  This,  of  course,  has  to  be  carefully  followed
n  registries,  which  need  to  be  established.  For  the  time
eing,  we  are  not  able  to  weight  the  beneﬁts  and  risks  of
DN  over  the  longer  tern,  which  is  the  time  scale  of  primary
revention  in  hypertension.
onclusions
here  is  a  great  hope  for  RDN,  as  this  technique  is  an  option
or  patients  with  RH;  and  the  indications  for  RDN  may  be
xtended  in  the  future,  depending  on  the  available  evi-
ence.  For  now,  the  medical  community  should  be  cautious
bout  proposing  RDN,  and  should  stick  ﬁrmly  to  the  current
ndications,  which  have  been  delineated  in  a  recent  French
onsensus  [4].  A  wider  use  of  this  approach  is  not  justiﬁed  for
ow.  Pharmacological  treatments  are  the  only  proven  way  to
revent  cardiovascular  events,  with  extensive  documenta-
ion  of  their  beneﬁt.  Their  tolerance  is  generally  good  (the
ide-effects  should  not  be  overstated),  as  is  their  efﬁcacy,
rovided  that  the  right  dosages  and  associations,  including
pironolactone,  are  used.  Not  using  effective  antihyper-
ensive  drugs  would  negate  several  decades  of  research
nd  efforts  in  hypertension  that  have  led  to  the  current
ptimized  blood  pressure  lowering  strategy  based  on  solid
vidence.
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[7] Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M.
Eligibility for renal denervation in patients with resistant hyper-
tension: when enthusiasm meets reality in real-life patients. JRenal  denervation  
However,  RDN  is  a  unique  opportunity  to  motivate  the
medical  community,  including  interventional  cardiologists,
to  a  rigorous  evaluation  of  hypertensive  patients  to  select
the  few  candidates  that  currently  can  be  referred  for  RDN
[7].  It  is  also  an  opportunity  to  look  more  systematically  to
secondary  forms  of  hypertension  and,  overall,  to  improve
blood  pressure  control  in  the  population,  even  if  it  is  not
through  extensive  use  of  RDN.  The  medical  community  has
a  major  responsibility  with  this  technique  to  avoid  missing
mandatory  steps  of  validation  —  with  important  opportuni-
ties  for  prospective  registries  —  to  progressively  ﬁnd  the  true
role  for  RDN  in  the  management  of  hypertension.  We  hope
that  wisdom  will  prevail.
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